SPDL1 and neoplasm: Analysis suggested that Apatinib combined with TMZ could significantly reduce sPD-L1 in patients, reduce its binding to sPD-1 receptor, promote T cell activation, and avoid cancer cells from escaping the anti-tumor immunity of the body.24